Objective: Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f-FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f-FTLD. We used a Bayesian linear mixed-effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods: Participants included 234 asymptomatic or prodromal carriers of C9orf72, GRN, or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1-weighted scans. The BLME models established individual voxel-wise gray matter trajectories using the first 2 scans. Person-specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time-varying Cox proportional hazard models covarying for age. Receiver-operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results: The BLME cluster volume predicted conversion to dementia in f-FTLD mutation carriers overall and separately in C9orf72, GRN, and MAPT, with comparable hazard ratios observed for atrophy W-maps and regional volumes. Within a 24-month timeframe, BLME cluster volume discriminated dementia converters from non-converters with larger areas under the curve (AUCs) than other approaches. Interpretation: Bayesian-modeled individualized atrophy scores predict dementia progression among asymptomatic f-FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a.

Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling / S. Dutt, D.L.. - In: ANNALS OF NEUROLOGY. - ISSN 0364-5134. - 99:5(2026 May), pp. 1315-1326. [10.1002/ana.78167]

Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling

D. Galimberti;
2026

Abstract

Objective: Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f-FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f-FTLD. We used a Bayesian linear mixed-effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods: Participants included 234 asymptomatic or prodromal carriers of C9orf72, GRN, or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1-weighted scans. The BLME models established individual voxel-wise gray matter trajectories using the first 2 scans. Person-specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time-varying Cox proportional hazard models covarying for age. Receiver-operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results: The BLME cluster volume predicted conversion to dementia in f-FTLD mutation carriers overall and separately in C9orf72, GRN, and MAPT, with comparable hazard ratios observed for atrophy W-maps and regional volumes. Within a 24-month timeframe, BLME cluster volume discriminated dementia converters from non-converters with larger areas under the curve (AUCs) than other approaches. Interpretation: Bayesian-modeled individualized atrophy scores predict dementia progression among asymptomatic f-FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a.
Settore BIOS-10/A - Biologia cellulare e applicata
mag-2026
29-gen-2026
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dutt et al.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 993.54 kB
Formato Adobe PDF
993.54 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1253735
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
  • OpenAlex 1
social impact